Is Sirtex's clinical trial result as bad as it seems?

Intelligent Investor

Independent Financial Research

Sirtex’s (ASX:SRX) share price fell 60% on March 17 after management announced the failure of a 7-year clinical trial. So why has one of the company’s largest shareholders increased its stake by 30%? SIRFLOX was the first of three Phase III trials that Sirtex hopes will provide doctors with enough data to support using the company’s SIR-Spheres as a first-line treatment for liver cancer. If successful, profits could increase several-fold. However, the study found that administering SIR-Spheres didn’t improve ‘overall progression-free survival’ – the amount of time following treatment where the cancer doesn’t get worse (the study’s ‘primary endpoint’). On the face of it, that’s a pretty scary result for a one-product company whose only claim is to slow the progression of liver cancer. But it’s actually not as bad as it seems. Read the full article: (VIEW LINK)


Intelligent Investor
Intelligent Investor
Independent Financial Research

Intelligent Investor is an independent financial research service with a 14-year history of beating the market. Our value investing approach empowers Australians to make more informed decisions to build their long-term wealth. We off structural...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

Comments

Sign In or Join Free to comment